Publications

Publications

Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.

Filter

All years 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008
All product lines Easy Easy PGX Helix Microsatelliti Myriapod Myriapod NGS Realquant Response
  • Response

Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. Future Medicine

  • Myriapod

Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status

  • Response

Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study

  • Response

Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study

  • Myriapod

Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. Oncology Letters

  • Myriapod

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. British Journal of Cancer

  • Myriapod

LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer

  • Myriapod

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

  • Easy

Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver. Pathology – Research and Practice

  • Myriapod

LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer. Lung Cancer Journal

Your next step starts here. Fill out the form and talk to us

Let's talk